.png){kind=icon}
.png){kind=icon}
Return
Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy
.png){kind=icon}
OA
AI
DOI：10.1186/s13046-024-03195-5.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Vigorous CD8(+) T cells play a crucial role in recognizing tumor cells and combating solid tumors. How T cells efficiently recognize and target tumor antigens, and how they maintain the activity in the rejection of solid tumor microenvironment, are major concerns. Recent advances in understanding of the immunological trajectory and lifespan of CD8(+) T cells have provided guidance for the design of more optimal anti-tumor immunotherapy regimens. Here, we review the newly discovered methods to enhance the function of CD8(+) T cells against solid tumors, focusing on optimizing T cell receptor (TCR) expression, improving antigen recognition by engineered T cells, enhancing signal transduction of the TCR-CD3 complex, inducing the homing of polyclonal functional T cells to tumors, reversing T cell exhaustion under chronic antigen stimulation, and reprogramming the energy and metabolic pathways of T cells. We also discuss how to participate in the epigenetic changes of CD8(+) T cells to regulate two key indicators of anti-tumor responses, namely effectiveness and persistence.
Keywords:
Immunotherapy
CD8(+) T cell
Solid tumor
Engineered T cell receptor -T cells
Immune checkpoint
T cell redirection
Gene editing
Immune reprogramming
Metabolic reprogramming
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
12.8
Papers:
4.4K
Citations:
2.9W